3 Oncology Generics, Branded Generics and Biologics Platform Stocks With a Strong Future Roadmap: Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare
- October 21, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare: ROE of 9.4% to 18.7% and FY22 to FY26 revenue CAGR of 7.5% to 21.0%. Prices as of 20 Oct 2026.
Quick Answer
The three specialty generics and oncology stocks to watch are Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare. Their return on equity ranges from 9.4% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 21.0%. Emcure Pharmaceuticals has the highest return on equity at 18.7%, while Natco Pharma has the fastest revenue growth at 21.0% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Specialty generics and oncology stocks let investors follow companies that make harder-to-copy medicines. Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare combine complex generics, branded generics in India and Europe, and an integrated oncology and biologics platform.
This list covers three specialty generics and oncology stocks with complete current figures: Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Specialty Generics and Oncology Stocks?
Specialty generics and oncology stocks are listed pharmaceutical companies that focus on complex generics, cancer medicines and biologics, which need more scientific skill than ordinary tablets. Their earnings depend on approvals, launches and the pace of capacity use.
Specialty Generics and Oncology Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Natco Pharma | 800.85 | 15,708 | 13.7 | 36.0 | 15.4 | 0.08 |
| Emcure Pharmaceuticals | 1,766.6 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
| Shilpa Medicare | 876.2 | 17,132 | 57.6 | 36.0 | 9.4 | 0.25 |
On valuation, Natco Pharma and Emcure Pharmaceuticals trade at a P/E below the industry P/E, while Shilpa Medicare trades above it, which reflects the growth the market already expects. Readers comparing specialty generics and oncology stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Specialty Generics and Oncology Stocks Have a Strong Roadmap in India?
Specialty generics and oncology stocks have a strong roadmap in India because cancer care and biologic medicines are growing categories where fewer producers can compete and prices hold up better.
- Cancer care demand. More diagnosis and treatment lifts demand for oncology medicines.
- Complex products. Hard-to-make generics face fewer competitors.
- Branded reach. Marketing arms in India and Europe build repeat demand.
Why Natco Pharma Features Among These Specialty Generics and Oncology Stocks
Among the specialty generics and oncology stocks on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.
Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.
The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.
Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.
Why Emcure Pharmaceuticals Features Among These Specialty Generics and Oncology Stocks
Among the complex generic shares on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Why Shilpa Medicare Features Among These Specialty Generics and Oncology Stocks
Among the three companies on this list, Shilpa Medicare, headquartered in Raichur, Karnataka, is a pharmaceutical company with active ingredients, formulations, biologics and contract development and manufacturing under one roof, with a focus on oncology.
Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%.
In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore. The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P/E of 57.6, above the industry P/E of 36.0.
Roadmap: Its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.
What to watch: Follow regulatory approvals and commercial launches, since these drive the timing of earnings.
Natco Pharma vs Emcure Pharmaceuticals vs Shilpa Medicare on Key Financials
The table below sets the three specialty generics and oncology stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Natco Pharma | 2,044 | 4,376 | 21.0% | 1,372 | 31.4% |
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
| Shilpa Medicare | 1,160 | 1,549 | 7.5% | 243 | 15.7% |
Emcure Pharmaceuticals posts the highest return on equity in this group at 18.7%. Emcure Pharmaceuticals has the largest FY26 revenue at Rs 9,335 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with specialty generics and oncology stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Specialty Generics and Oncology Stocks
Every theme carries risks that deserve a check before any decision. For these specialty generics and oncology stocks, the main points are: Long-term complex generic shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Approval timelines. Launches depend on regulatory decisions that can shift.
- Pricing pressure. Competition can reduce prices once products are widely available.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter specialty generics and oncology stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Specialty Generics and Oncology Stocks
Specialty generics and oncology stocks reward investors who track approvals, launches and capacity use together. Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare each pursue growth in higher-value segments. Based on the 20 October 2026 close, Natco Pharma trades at Rs 800.85, Emcure Pharmaceuticals at Rs 1,766.6 and Shilpa Medicare at Rs 876.2.
Download the Univest iOS App or Univest Android App to track specialty generics and oncology stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are specialty generics and oncology stocks?
Ans. Specialty generics and oncology stocks are listed pharmaceutical companies that focus on complex generics, cancer medicines and biologics, which need more scientific skill than ordinary tablets. Their earnings depend on approvals, launches and the pace of capacity use. This list looks at three of them, Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which specialty generics and oncology stocks are covered in this list?
Ans. This list covers Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare. Based on the 20 October 2026 close, Natco Pharma traded at Rs 800.85, Emcure Pharmaceuticals at Rs 1,766.6 and Shilpa Medicare at Rs 876.2. Their return on equity ranges from 9.4% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 21.0%.
Why do specialty generics and oncology stocks have a strong future roadmap in India?
Ans. Specialty generics and oncology stocks have a strong roadmap in India because cancer care and biologic medicines are growing categories where fewer producers can compete and prices hold up better. The main drivers are as follows. Cancer care demand. More diagnosis and treatment lifts demand for oncology medicines. Complex products. Hard-to-make generics face fewer competitors. Branded reach. Marketing arms in India and Europe build repeat demand. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Natco Pharma performed financially?
Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
How has Shilpa Medicare performed financially?
Ans. Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%. In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore. The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P/E of 57.6, above the industry P/E of 36.0. Looking ahead, its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.
What risks should investors check before buying specialty generics and oncology stocks?
Ans. Investors should check a few risks before buying specialty generics and oncology stocks. Approval timelines. Launches depend on regulatory decisions that can shift. Pricing pressure. Competition can reduce prices once products are widely available. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of specialty generics and oncology stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
